Barbara Ryan

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.

While Q3 numbers look bleak, is improvement on the horizon?

When was the last time a big pharma’s shares massively outperformed a biotech index YTD? Hint: You likely weren’t around.

But could there be a shift in momentum?